title: Synergistic antivirus effect of combined administration of Combivir with Angelica polysaccharide sulfate.
abstract: This study is to investigate the synergistic effect of Anglica polysaccharide sulfate (APS-1) and Combivir, an anti-AIDS drug, on murine leukemia virus in vivo. As the results shown, the virus replication was significantly decreased by the combination of APS-1 and Combivir, which tended to be further decreased (58% inhibition) when compared with that of Combivir alone (51% inhibition). Furthermore, both the percentage of CD4(+) cells and CD4(+)/CD8(+) ratio in peripheral blood cells were significantly enhanced by this combined administration, while the CD4(+) cells was only slightly increased and CD4(+)/CD8(+) ratio was not affected by Combivir alone. Additionally, combination of APS-1 and Combivir also alleviated the toxicity of Combivir. APS-1 not only increased the survival rate of mice administered with LD(50) dose of Combivir, but also reduced the hematologic toxicity induced by Combivir, RBC, HGB and PLT were restored to normal level. These results suggest that APS-1 had synergistic effect with Combivir, which provided new insight into the potential clinical use of polysaccharide sulfate in anti-AIDS field.
authors.affiliation: Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China. thyang72@hotmail.com
authors.forename: Tiehong
authors.initials: T
authors.lastname: Yang
authors.forename: Min
authors.initials: M
authors.lastname: Jia
authors.forename: Zhenggang
authors.initials: Z
authors.lastname: Yue
authors.forename: Ying
authors.initials: Y
authors.lastname: Cheng
authors.forename: Xinxin
authors.initials: X
authors.lastname: Zhang
authors.forename: Junjie
authors.initials: J
authors.lastname: Huang
authors.forename: Siyuan
authors.initials: S
authors.lastname: Zhou
authors.forename: Qibing
authors.initials: Q
authors.lastname: Mei
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000633:toxicity; D001854:Bone Marrow Cells / Q000187:drug effects; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology; D045744:Cell Line, Tumor; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology* / Q000633:toxicity; D007928:Lethal Dose 50; D009052:Leukemia Virus, Murine / Q000187:drug effects / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009929:Organ Size / Q000187:drug effects; D011134:Polysaccharides / Q000494:pharmacology* / Q000633:toxicity; D013950:Thymus Gland / Q000187:drug effects / Q000473:pathology; D019562:Viral Load; D014779:Virus Replication / Q000187:drug effects*; D015215:Zidovudine / Q000494:pharmacology* / Q000633:toxicity
chemical_list: C581367:APS-1 polysaccharide sulfate; D019380:Anti-HIV Agents; D004338:Drug Combinations; D011134:Polysaccharides; C109078:lamivudine, zidovudine drug combination; D019259:Lamivudine; D015215:Zidovudine